

## Expenditures for Medicaid Patients Treated With Exenatide Compared With Other Diabetes Management Regimens

This supplement to *The American Journal of Managed Care* reports results from a retrospective cohort analysis of Medicaid claims data designed to compare Medicaid spending among patients with type 2 diabetes mellitus receiving exenatide, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, or basal insulin as add-on antidiabetic therapy. It also discusses the implications and limitations of these study results.

### ■ Faculty

#### **Jennie H. Best, PhD**

Director, Health Economics and Outcomes Research  
Medical Research and Development  
Amylin Pharmaceuticals, Inc  
San Diego, California

#### **Ryan M. Conrad, PhD**

Economist  
Precision Health Economics, LLC  
Los Angeles, California

#### **Dana P. Goldman, PhD**

Norman Topping Chair in Medicine and Public Policy  
Price School of Public Policy

Director  
Leonard D. Schaeffer Center for Health Policy and Economics  
University of Southern California  
Los Angeles, California

### ■ Faculty Disclosures

These faculty report relationships with the following organizations:

#### **Jennie H. Best, PhD**

*Employee and stock ownership:*  
Amylin Pharmaceuticals, Inc

#### **Ryan M. Conrad, PhD**

*Consultant:*  
Amylin Pharmaceuticals, Inc

#### **Dana P. Goldman, PhD**

*Consultant:*  
Amylin Pharmaceuticals, Inc

#### **Anne L. Peters, MD**

*Consultant:*  
Amylin Pharmaceuticals, Inc, Boehringer Ingelheim, CellNovo, Lilly, Novo Nordisk, sanofi-aventis

#### *Honoraria:*

Dexcom, Medtronic MiniMed, Merck, Medscape, Perrigo

#### *Speakers' bureau:*

Amylin Pharmaceuticals, Inc, Takeda, Lilly, Novo Nordisk

#### **John A. Romley, PhD**

*Consultant:*  
Amylin Pharmaceuticals, Inc

#### **Anne L. Peters, MD**

Professor  
Division of Endocrinology  
Keck School of Medicine

Director  
Clinical Diabetes Program  
University of Southern California  
Los Angeles, California

#### **John A. Romley, PhD**

Research Assistant Professor  
Price School of Public Policy  
University of Southern California  
Los Angeles, California

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

---

# *Expenditures for Medicaid Patients Treated With Exenatide Compared With Other Diabetes Management Regimens*

This supplement was supported by **Amylin Pharmaceuticals, Inc.**

• • •

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.